Journal of Peking University (Health Sciences) ›› 2021, Vol. 53 ›› Issue (4): 740-743. doi: 10.19723/j.issn.1671-167X.2021.04.020

Previous Articles     Next Articles

Application of Rotarex mechanical thrombectomy system in treating in-stent restenosis of lower extremity arteriosclerosis obliterans

ZHUANG Jin-man,LI Tian-run,LI Xuan(),LUAN Jing-yuan,WANG Chang-ming,FENG Qi-chen,HAN Jin-tao   

  1. Department of Intervention Vascular Surgery, Peking University Third Hospital, Beijing 100191, China
  • Received:2019-08-01 Online:2021-08-18 Published:2021-08-25
  • Contact: Xuan LI E-mail:13701091788@139.com

Abstract:

Objective: To evaluate the role of Rotarex mechanical thrombectomy system in treating instent restenosis of peripheral artery disease (PAD). Methods: The clinical data of 7 in-stent restenosis (ISR) cases of lower extremity PAD from June 2017 to Dec 2018 were retrospectively analyzed. There were 5 males and 2 females and the mean age was (70.0±7.6) years from 59.0 to 76.0 years. All the cases were treated by Rotarex mechanical thrombectomy system. In the 7 cases, time interval from the previous stent implantation to ischemia recurrence was 1.0 to 72.0 months, and the median time was 6.0 months. The period from ischemia recurrence to endovascular therapy was 3 days to 2 years, and the median time was 62 days. Rotarex mechanical debulking catheter and percutaneous transluminal angioplasty (PTA) were used in all the cases, and the stent was used only when it was necessary. Anticoagulation was used for 24 hours after procedures and then antiplatelet agents were used as usual. Doppler ultrasonography was taken during the followed-up. Results: All the 7 cases were successful in technology, 3 of which were implanted with new stents for the fracture of the old ones. while for the other four cases, no new stent was implanted. The ankle-brachial index (ABI) increased from 0.31±0.08 to 0.86±0.08 after treatment (t=-12.84, P<0.001). Thrombectomy was applied urgently in one case because of acute thrombosis in the stent, and the result was good. There was no other complications in hospital. All the patients were followed up for 5.0-22.0 months, and the median time was 14.0 months. No death and amputation occurred during the follow-up. One patient stopped antiplatelet agents because of gastrointestinal bleeding, which resulted in acute thrombosis. in-stent restenosis reappeared in 3 cases. Conclusion: Debulking using Rotarex catheter is safe and effective in treating in-stent restenosis of PAD, especially in reducing stents implantation, but is not good at dealing with old thrombus and proliferating intima, and can do nothing about fractured stents and hyperplasia of intima, so it needs to be combined with stents and drug coated balloons.

Key words: Peripheral artery disease, In-stent restenosis, Mechanical thrombectomy catheter, Debulking

CLC Number: 

  • R654.4

Table 1

General condition of patients"

Case Gender Age/years LD LL/cm LO/cm RC ABI SF
1 M 73 SFA 25.0 20.0 3 0.32 Yes
2 M 59 SFA 40.0 15.0 4 0.26 Yes
3 M 76 SFA,PA 45.0 40.0 3 0.36 No
4 M 74 SFA,PA 45.0 40.0 4 0.18 No
5 M 59 SFA 30.0 30.0 3 0.35 No
6 F 75 CIA 4.0 4.0 4 0.42 No
7 F 74 SFA 30.0 30.0 3 0.26 Yes

Table 2

Results of treatment and follow up"

Cases DCB Stent Complications RC ABI Follow-up/months Restenosis
1 No Yes No 1 0.85 22 Yes
2 No Yes No 1 0.82 18 Yes
3 yes No No 1 0.91 15 No
4 yes No No 2 0.72 14 Yes
5 No No No 1 0.92 13 Yes
6 No No AT 1 0.96 12 No
7 yes Yes No 1 0.82 5 No
[1] 符伟国, 岳嘉宁. 股胭动脉段病变支架内再狭窄的腔内治疗策略分析 [J]. 中华外科杂志, 2016, 8(54):8586-8590
[2] Donato G, Arturo A, Tullio T, et al. Drug-coated balloon in superficial femoral artery in-stent restenosis [J]. Adv Interv Cardiol, 2018, 14(51):9-14.
[3] Yang X, Lu X, Li W, et al. Endovascular treatment for sympto-matic stent failures in long-segment chronic total occlusion of femoropopliteal arteries [J]. J Vasc Surg, 2014, 60(2):362-368.
doi: 10.1016/j.jvs.2014.02.051
[4] Liistro F, Grotti S, Porto I, et al. Drug-eluting balloon in peri-pheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial [J]. JACC Cardiovasc Interv, 2013, 6(12):1295-1302.
doi: 10.1016/j.jcin.2013.07.010
[5] Antoniou GA, Georgakarakos EI, Antoniou SA, et al. Does endovascular treatment of infra-inguinal arterial disease with drug-eluting stents offer better results than angioplasty with or without bare metal stents [J]. Interact Cardiovasc Thorac Surg, 2014, 19(2):282-285.
doi: 10.1093/icvts/ivu093
[6] Wissgott C, Kamusella P, Andresen R, et al. Treatment of in-stent reocclusions of femoropopliteal arteries with mechanical rotational catheters [J]. Fortschr Röntgenstr, 2011, 183(10):939-944.
doi: 10.1055/s-0031-1281634
[7] Heller S, Lubanda JC, Varejka P, et al. Percutaneous mechanical thrombectomy using Rotarex device in acute limb ischemia in infrainguinal occlusions [J]. Biomed Res Int, 2017, 5(7):1-8.
[8] 张艳, 林洋, 李承志, 等. 机械除栓导管治疗下肢动脉硬化闭塞症支架内再狭窄应用的临床研究 [J]. 中华放射学杂志, 2017, 51(9):699-703.
[9] Karen J, Christopher D. Diagnosis, classification, and treatment of femoropopliteal artery in-stent restenosis [J]. J Vasc Surg, 2017, 65(2):545-557.
doi: S0741-5214(16)31272-1 pmid: 28126181
[10] Tosaka A, Soga Y, Iida O, et al. Classification and clinical impact of restenosis after femoropopliteal stenting [J]. JACC, 2012, 59(1):16-23.
doi: 10.1016/j.jacc.2011.09.036
[11] Scheer F, Lüdtke CW, Kamusella P, et al. Combination of rotational atherothrombectomy and paclitaxel-coated angioplasty for femoropopliteal occlusion [J]. Clin Med Insights Cardiol, 2015, 21(8):43-48.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] Author. English Title Test[J]. Journal of Peking University(Health Sciences), 2010, 42(1): 1 -10 .
[2] . [J]. Journal of Peking University(Health Sciences), 2009, 41(2): 188 -191 .
[3] . [J]. Journal of Peking University(Health Sciences), 2009, 41(3): 376 -379 .
[4] . [J]. Journal of Peking University(Health Sciences), 2009, 41(4): 459 -462 .
[5] . [J]. Journal of Peking University(Health Sciences), 2009, 41(6): 682 -686 .
[6] . [J]. Journal of Peking University(Health Sciences), 2010, 42(1): 82 -84 .
[7] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 319 -322 .
[8] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 333 -336 .
[9] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 337 -340 .
[10] . [J]. Journal of Peking University(Health Sciences), 2007, 39(3): 225 -328 .